AdipoGen Life Sciences

Thiocolchicoside

CHF 55.00
In stock
AG-CN2-0076-M0011 mgCHF 55.00
AG-CN2-0076-M0055 mgCHF 95.00
AG-CN2-0076-M02525 mgCHF 380.00
More Information
Product Details
Synonyms BRN 0072205; NSC 147755; Coltramyl; 10-thio-Colchicoside; 2-Demethoxy-2-glucosidoxythiocolchicine
Product Type Chemical
Properties
Formula

C27H33NO10S

MW 563.6
Merck Index 14: 9324
CAS 602-41-5
Source/Host Chemicals Semisynthetic.
Purity Chemicals ≥95% (NMR)
Appearance Yellow solid.
Solubility Soluble in water or ethanol.
Identity Determined by 1H-NMR.
InChi Key LEQAKWQJCITZNK-MSQQGMGVSA-N
Smiles COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CCC(NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Potent competitive γ-aminobutyric acid type A (GABAA) receptor antagonist and glycine receptor agonist.
  • Weak nicotinic acetylcholine receptor agonist.
  • Muscle relaxant.
  • Anti-inflammatory. Has analgesic properties.
  • Shows strong epileptogenic and convulsant activity.
  • Anticancer compound through inhibition of NF-κB and NF-κB-regulated gene products
  • Apoptosis inducer.
  • Suppressed osteoclastogenesis induced by RANKL and tumor cells via the NF-κB signaling pathway.
  • Therapeutic option for the management of bone metastatic disease.
Product References
  1. Affinity of thiocolchicoside and thiocolchicoside analogues for the postsynaptic GABA receptor site: K. Biziere, et al.; Eur. J. Pharmacol. 75, 167 (1981)
  2. Review of the toxicology, pharmacodynamics and pharmacokineticss of thiocolchicoside, a GABA-agonist muscle relaxant with anti-inflammatory and analgesic actions: J.M. Janbroers; Acta Ther. 13, 221 (1987)
  3. Interaction of thiocolchicoside with [3H]strychnine binding sites in rat spinal cord and brainstem: M. Cimino, et al.; Eur. J. Pharmacol. 318, 201 (1996)
  4. Focal and secondarily generalised convulsive status epilepticus induced by thiocolchicoside in the rat: G. Sechi, et al.; Seizure 12, 508 (2003)
  5. Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain: F. Tüzün, et al.; Joint Bone Spine 70, 356 (2003)
  6. The muscle relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system: M. Carta, et al.; Neuropharmacology 51, 805 (2006)
  7. Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes: M.P. Mascia, et al.; Eur. J. Pharmacol. 558, 37 (2007)
  8. Thiocolchicoside exhibits anticancer effects through downregulation of NF-κB pathway and its regulated gene products linked to inflammation and cancer: S. Reuter, et al.; Cancer Prev. Res. 3, 1462 (2010)
  9. Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug: S. Reuter, et al.; Br. J. Pharmacol.  165, 2127 (2012)
  10. Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption? O. Micheau, et al.; Br. J. Pharmacol. 165, 2124 (2012)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.